Speaker: Alberto Neder, MD, Queen’s University, Kingston, ON
Moderator: Erika Penz, MD, MSc, FRCPC, University of Saskatchewan, Saskatoon, SK
COPD is the third leading cause of death worldwide, and 1 in 5 patients with COPD die within 1 year of their first hospitalization for an exacerbation. The impact of an exacerbation goes beyond the lungs – following an exacerbation, patients have a greater increased risk of MI, stroke and other CV events. The goal of this session is to shed light on the relationship between exacerbation and increased mortality risk and help HCPs identify patients at risk for future exacerbations.
At the end of this presentation, attendees will be able to:
- Describe the relationship between exacerbations and increased mortality risk (including CV risk);
- Discuss emerging data to support the use of triple therapies on reducing patient mortality;
- Identify patients at risk for exacerbations (and why they tend to underreport); and
- Examine life changing clinical practice approaches to improving patient quality of life.
CanMEDS roles addressed: Health Advocate, Medical Expert, Scholar
This session is co-developed by the Canadian Thoracic Society and AstraZeneca and is planned to achieve scientific integrity, objectivity and balance.